| 1 |
Kole E, Jadhav K, Sirsath N, Dudhe P, Verma RK, Chatterjee A, Naik J. Nanotherapeutics for pulmonary drug delivery: An emerging approach to overcome respiratory diseases. Journal of Drug Delivery Science and Technology 2023. [DOI: 10.1016/j.jddst.2023.104261] [Reference Citation Analysis]
|
| 2 |
Alipour S, Mahmoudi L, Ahmadi F. Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19. Drug Deliv Transl Res 2023;13:705-15. [PMID: 36260223 DOI: 10.1007/s13346-022-01251-1] [Reference Citation Analysis]
|
| 3 |
Awad H, Hassan B, Dweek S, Aboelata Y, Rawas-qalaji M, Ahmed IS. Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19. Pharmaceuticals 2022;15:1068. [DOI: 10.3390/ph15091068] [Reference Citation Analysis]
|
| 4 |
Barati N, Motavallihaghi S, Nikfar B, Chaichian S, Momtazi-Borojeni AA. Potential therapeutic effects of Ivermectin in COVID-19. Exp Biol Med (Maywood) 2022;247:1388-96. [PMID: 35686662 DOI: 10.1177/15353702221099579] [Reference Citation Analysis]
|
| 5 |
Saha T, Quiñones-Mateu ME, Das SC. Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. Int J Pharm 2022;624:122042. [PMID: 35868481 DOI: 10.1016/j.ijpharm.2022.122042] [Reference Citation Analysis]
|
| 6 |
Saha T, Sinha S, Harfoot R, Quiñones-Mateu ME, Das SC. Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder. Pharmaceutics 2022;14. [PMID: 35890327 DOI: 10.3390/pharmaceutics14071432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Oriola AO, Oyedeji AO. Plant-Derived Natural Products as Lead Agents against Common Respiratory Diseases. Molecules 2022;27:3054. [PMID: 35630531 DOI: 10.3390/molecules27103054] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 8 |
Shukla AK, Misra S. Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic. J Basic Clin Physiol Pharmacol 2022. [PMID: 35503307 DOI: 10.1515/jbcpp-2022-0061] [Reference Citation Analysis]
|
| 9 |
Albariqi AH, Wang Y, Yoon Kyung Chang R, Quan DH, Wang X, Kalfas S, Drago J, Britton WJ, Chan HK. Pharmacokinetics and Safety of Inhaled Ivermectin in Mice as a Potential COVID-19 Treatment. Int J Pharm 2022;:121688. [PMID: 35314278 DOI: 10.1016/j.ijpharm.2022.121688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Albariqi AH, Ke WR, Khanal D, Kalfas S, Tang P, Britton WJ, Drago J, Chan HK. Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy. J Aerosol Med Pulm Drug Deliv 2022. [PMID: 35275749 DOI: 10.1089/jamp.2021.0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Chable-bessia C, Boullé C, Neyret A, Swain J, Hénaut M, Merida P, Gros N, Makinson A, Lyonnais S, Chesnais C, Muriaux D. Low Selectivity Indices of Ivermectin and Macrocyclic Lactones on SARS-CoV-2 Replication In Vitro. COVID 2022;2:60-75. [DOI: 10.3390/covid2010005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 12 |
Vasilchenko MK, Ivannikov AA, Yesaulenko AN, Alidzhanova KG, Petrikov SS. COVID-19 and Cardiovascular System. Part 3. COVID-19 Current Treatment Approaches: Evidence-Based Review. Neotložnaâ med pomoŝʹ 2021;10:438-451. [DOI: 10.23934/2223-9022-2021-10-3-438-451] [Reference Citation Analysis]
|
| 13 |
Khairnar SV, Jain DD, Tambe SM, Chavan YR, Amin PD. Nebulizer systems: a new frontier for therapeutics and targeted delivery. Ther Deliv 2021;:0. [PMID: 34766509 DOI: 10.4155/tde-2021-0070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Chable-bessia C, Boullé C, Neyret A, Swain J, Hénaut M, Merida P, Gros N, Makinson A, Lyonnais S, Chesnais CB, Muriaux D. Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.. [DOI: 10.1101/2021.11.01.466865] [Reference Citation Analysis]
|
| 15 |
Brain D, Plant-Hately A, Heaton B, Arshad U, David C, Hedrich C, Owen A, Liptrott NJ. Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Adv Drug Deliv Rev 2021;178:113848. [PMID: 34182016 DOI: 10.1016/j.addr.2021.113848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 16 |
Khandelwal A, Singh GP, Jamil S. Ivermectin as a multifaceted drug in COVID-19: Current insights. Med J Armed Forces India 2021;77:S254-6. [PMID: 34334890 DOI: 10.1016/j.mjafi.2021.06.002] [Reference Citation Analysis]
|
| 17 |
M Mansour S, N Shamma R, A Ahmed K, A Sabry N, Esmat G, A Mahmoud A, Maged A. Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. Int Immunopharmacol 2021;99:108004. [PMID: 34333358 DOI: 10.1016/j.intimp.2021.108004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 18 |
Chandel V, Tripathi G, Nayar SA, Rathi B, Kumar A, Kumar D. In silico identification and validation of triarylchromones as potential inhibitor against main protease of severe acute respiratory syndrome coronavirus 2. J Biomol Struct Dyn 2022;40:8850-65. [PMID: 33939590 DOI: 10.1080/07391102.2021.1918255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 19 |
Vicente B, López-Abán J, Chaccour J, Hernández-Goenaga J, Nicolas P, Fernández-Soto P, Muro A, Chaccour C. The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice. Sci Rep 2021;11:4476. [PMID: 33627744 DOI: 10.1038/s41598-021-84009-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 20 |
Olum S, Scolding P, Hardy C, Obol J, Scolding NJ. Response to: 'Nodding syndrome, many questions remain but we can prevent it by eliminating onchocerciasis'. Brain Commun 2021;3:fcaa229. [PMID: 33502386 DOI: 10.1093/braincomms/fcaa229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 21 |
Errecalde J, Lifschitz A, Vecchioli G, Ceballos L, Errecalde F, Ballent M, Marín G, Daniele M, Turic E, Spitzer E, Toneguzzo F, Gold S, Krolewiecki A, Alvarez L, Lanusse C. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. J Pharm Sci 2021;110:2501-7. [PMID: 33493479 DOI: 10.1016/j.xphs.2021.01.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 22 |
Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, Richardson MA, Rodríguez-Mateos M, Jordán-Iborra C, Brew J, Carmona-Torre F, Giráldez M, Laso E, Gabaldón-Figueira JC, Dobaño C, Moncunill G, Yuste JR, Del Pozo JL, Rabinovich NR, Schöning V, Hammann F, Reina G, Sadaba B, Fernández-Alonso M. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine 2021;32:100720. [PMID: 33495752 DOI: 10.1016/j.eclinm.2020.100720] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 56.5] [Reference Citation Analysis]
|
| 23 |
Manikkath J. Innovations in drug-device combinations for delivering medication to the airways. Airway 2021;4:13. [DOI: 10.4103/arwy.arwy_15_21] [Reference Citation Analysis]
|
| 24 |
[DOI: 10.1101/2020.11.30.20236570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
|
